Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2008

01.02.2008 | Preclinical Study

Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIPL

verfasst von: Natalya V. Guseva, Oskar W. Rokhlin, Agshin F. Taghiyev, Michael B. Cohen

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

The majority of breast cancer cell lines are resistant to tumor necrosis factor -related apoptosis inducing ligand (TRAIL) induced apoptosis. TRAIL and Fas receptor death-inducing signaling complex (DISCs) formation are similar and involve ligand-dependent recruitment of FADD and caspase-8. We have found that the breast carcinoma cell line T47D is an unusual example of selective sensitivity to anti-Fas mAb treatment but resistant to TRAIL. Therefore, a detailed comparison of these two signaling pathways in one cell line should provide insight into the mechanism of TRAIL resistance. We observed that only anti-Fas mAb induces caspase activation and cell death in T47D. Further, FADD and caspase-8 interact with both TRAIL-R1 and TRAIL-R2, and that the amount of caspase-8 recruited by Fas-, TRAIL-R1 and TRAIL-R2 are the same. cFLIPS and cFLIPR isoforms block death receptor-induced apoptosis by inhibiting caspase-8 activation at the DISC; the role of cFLIPL at the DISC is still controversial. It has been suggested that the presence of the cleaved form of FLIPL-p43 at the DISC prevents caspase-8 cleavage. We found that both TRAIL and anti-Fas mAb-induced DISCs contain the cleaved form of p43 cFLIPL and its amount at the Fas DISC was higher compared to the TRAIL DISC. We also found that inhibition of cFLIPL expression in T47D cells decreased Fas-mediated caspase-8 activation and activation of effector caspases. We propose that in T47D p43 cFLIPL in the Fas-DISC may promote caspase-8 activation. The mechanism by which different amounts of p43cFLIPL regulates caspase-8 activation remains to be investigated.
Literatur
1.
Zurück zum Zitat Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305–1308PubMedCrossRef Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281:1305–1308PubMedCrossRef
2.
Zurück zum Zitat Ashkenazi A, Dixit VM (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255–260PubMedCrossRef Ashkenazi A, Dixit VM (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255–260PubMedCrossRef
3.
Zurück zum Zitat Irmler M, Thome M, Hahne M, Schneider P, Hofman K, Steiner V, Bodmer JL, Schhroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190–195PubMedCrossRef Irmler M, Thome M, Hahne M, Schneider P, Hofman K, Steiner V, Bodmer JL, Schhroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190–195PubMedCrossRef
4.
Zurück zum Zitat TschoppJ, Irmler M, Thome M (1998) Inhibition of Fas death signals by FLIPs. Curr Opin Immunol 10:552–558CrossRef TschoppJ, Irmler M, Thome M (1998) Inhibition of Fas death signals by FLIPs. Curr Opin Immunol 10:552–558CrossRef
5.
Zurück zum Zitat Golks A, Brenner D, Fritsch C, Krammer PH, Layrik IN (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280:14507–14513PubMedCrossRef Golks A, Brenner D, Fritsch C, Krammer PH, Layrik IN (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280:14507–14513PubMedCrossRef
6.
Zurück zum Zitat Kruger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S (2001) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276:20633–20640CrossRef Kruger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S (2001) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276:20633–20640CrossRef
7.
Zurück zum Zitat Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW, Briand C, Grutter MG (2002) The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277:45162–45171PubMedCrossRef Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW, Briand C, Grutter MG (2002) The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277:45162–45171PubMedCrossRef
8.
Zurück zum Zitat Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4), 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB (1997) Immunity 7:831–836 Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4), 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB (1997) Immunity 7:831–836
9.
Zurück zum Zitat Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7:821–830PubMedCrossRef Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7:821–830PubMedCrossRef
10.
Zurück zum Zitat Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkoowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59:734–741PubMed Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkoowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59:734–741PubMed
11.
Zurück zum Zitat Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111–113PubMedCrossRef Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111–113PubMedCrossRef
12.
Zurück zum Zitat Griffith TS, Chin WA, Jackon GC, Lynch DH, Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833–2840PubMed Griffith TS, Chin WA, Jackon GC, Lynch DH, Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833–2840PubMed
13.
Zurück zum Zitat Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813–820PubMedCrossRef Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813–820PubMedCrossRef
14.
Zurück zum Zitat Rokhlin OW, Guseva N, Taghiyev A, Knudson CM, Cohen MB (2001) Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Oncogene 20:2836–2843PubMedCrossRef Rokhlin OW, Guseva N, Taghiyev A, Knudson CM, Cohen MB (2001) Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis. Oncogene 20:2836–2843PubMedCrossRef
15.
Zurück zum Zitat Rokhlin OW, Glover RA, Cohen MB (1998) Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res 58:5870–5875PubMed Rokhlin OW, Glover RA, Cohen MB (1998) Fas-mediated apoptosis in human prostatic carcinoma cell lines occurs via activation of caspase-8 and caspase-7. Cancer Res 58:5870–5875PubMed
16.
Zurück zum Zitat Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB. (2004) Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines. Cancer Biol Ther 3:761–768PubMedCrossRef Rokhlin OW, Guseva NV, Taghiyev AF, Glover RA, Cohen MB. (2004) Multiple effects of N-alpha-tosyl-L-phenylalanyl chloromethyl ketone (TPCK) on apoptotic pathways in human prostatic carcinoma cell lines. Cancer Biol Ther 3:761–768PubMedCrossRef
17.
Zurück zum Zitat Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB (2002) Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 52:1–11PubMedCrossRef Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB (2002) Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 52:1–11PubMedCrossRef
18.
Zurück zum Zitat Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM (2004) Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304:596–600PubMedCrossRef Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM (2004) Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304:596–600PubMedCrossRef
19.
Zurück zum Zitat Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vicic D, Ashkenazi A (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280:40599–40608PubMedCrossRef Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vicic D, Ashkenazi A (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280:40599–40608PubMedCrossRef
20.
Zurück zum Zitat Jin TG, Kurakin A, Benhaga N, Abe K, Mohseni M, Sandra F, Song K, Kay BK, Khosravi-Far R (2004) Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. J Biol Chem 279:55594–55601PubMedCrossRef Jin TG, Kurakin A, Benhaga N, Abe K, Mohseni M, Sandra F, Song K, Kay BK, Khosravi-Far R (2004) Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. J Biol Chem 279:55594–55601PubMedCrossRef
21.
Zurück zum Zitat Yang BF, Xao C, Roa Wh, Krammer PH, Hao C (2003) Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J Biol Chem 278:7043–7050PubMedCrossRef Yang BF, Xao C, Roa Wh, Krammer PH, Hao C (2003) Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J Biol Chem 278:7043–7050PubMedCrossRef
22.
Zurück zum Zitat Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C (2005) Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exp Cell Res 304:244–255PubMedCrossRef Xiao C, Yang BF, Song JH, Schulman H, Li L, Hao C (2005) Inhibition of CaMKII-mediated c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exp Cell Res 304:244–255PubMedCrossRef
Metadaten
Titel
Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIPL
verfasst von
Natalya V. Guseva
Oskar W. Rokhlin
Agshin F. Taghiyev
Michael B. Cohen
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9563-2

Weitere Artikel der Ausgabe 3/2008

Breast Cancer Research and Treatment 3/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.